DK3571224T3 - Forbedrede serumalbuminbindere - Google Patents

Forbedrede serumalbuminbindere Download PDF

Info

Publication number: DK3571224T3
Authority: DK; Denmark
Prior art keywords: serum albumin; improved serum; albumin binders; binders; improved
Prior art date: 2017-01-17

Application number

DK18703213.1T

Other languages

English (en)

Inventor

Stephanie Staelens

Soren Steffensen

An Cerdobbel

Erika Morizzo

Original Assignee

Ablynx Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-01-17

Filing date

2018-01-17

Publication date

2024-11-11

2018-01-17 Application filed by Ablynx Nv filed Critical Ablynx Nv

2024-11-11 Application granted granted Critical

2024-11-11 Publication of DK3571224T3 publication Critical patent/DK3571224T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

DK18703213.1T 2017-01-17 2018-01-17 Forbedrede serumalbuminbindere DK3571224T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762446992P	2017-01-17	2017-01-17
PCT/EP2018/051082 WO2018134234A1 (en)	2017-01-17	2018-01-17	Improved serum albumin binders

Publications (1)

Publication Number	Publication Date
DK3571224T3 true DK3571224T3 (da)	2024-11-11

Family

ID=61163666

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK18703213.1T DK3571224T3 (da)	2017-01-17	2018-01-17	Forbedrede serumalbuminbindere

Country Status (22)

Country	Link
US (2)	US11897944B2 (da)
EP (3)	EP3571224B1 (da)
JP (3)	JP7300385B2 (da)
KR (2)	KR20230165374A (da)
CN (2)	CN117327175A (da)
AU (2)	AU2018209150B2 (da)
BR (1)	BR112019014600A2 (da)
CA (1)	CA3050574A1 (da)
DK (1)	DK3571224T3 (da)
ES (1)	ES2994387T3 (da)
FI (1)	FI3571224T3 (da)
HR (1)	HRP20241501T1 (da)
HU (1)	HUE068820T2 (da)
IL (3)	IL305912B2 (da)
LT (1)	LT3571224T (da)
MX (4)	MX2019008536A (da)
PL (1)	PL3571224T3 (da)
PT (1)	PT3571224T (da)
RS (1)	RS66173B1 (da)
SG (2)	SG11201906341XA (da)
SI (1)	SI3571224T1 (da)
WO (1)	WO2018134234A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20250099289A (ko)	2014-05-16	2025-07-01	아블린쓰 엔.브이.	개선된 면역글로불린 가변 도메인
PL3248986T3 (pl)	2014-05-16	2022-05-16	Ablynx Nv	Domeny zmienne immunoglobuliny
RU2022101604A (ru) *	2016-12-07	2022-03-29	Аблинкс Нв	Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
HRP20241501T1 (hr) *	2017-01-17	2025-01-03	Ablynx Nv	Poboljšana veziva albumina u serumu
SG10202108972RA (en) *	2017-01-17	2021-09-29	Ablynx Nv	Improved serum albumin binders
JP7657797B2 (ja)	2019-12-06	2025-04-07	アブリンクスエン．ヴェー．	ＴＮＦαおよびＩＬ－２３を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
PH12022551231A1 (en)	2019-12-06	2023-07-31	Ablynx Nv	Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
WO2021116182A1 (en)	2019-12-09	2021-06-17	Ablynx Nv	Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
IL296767A (en)	2020-03-30	2022-11-01	Ablynx Nv	A method for the production and purification of single variable multivalent immunoglobulin sites
MX2023003522A (es)	2020-09-25	2023-04-19	Ablynx Nv	Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
WO2022089435A1 (en)	2020-10-27	2022-05-05	Beijing Ql Biopharmaceutical Co., Ltd.	Fusion proteins of gdf15 and use thereof
KR20230123497A (ko)	2020-12-18	2023-08-23	아블린쓰 엔.브이.	IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드
KR20230123495A (ko)	2020-12-18	2023-08-23	아블린쓰 엔.브이.	글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드
KR20230122084A (ko)	2020-12-18	2023-08-22	아블린쓰 엔.브이.	Tcr 알파/베타 반응성에 기초한 t 세포 동원 폴리펩타이드
AU2022409733A1 (en)	2021-12-17	2024-08-01	Ablynx Nv	POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
EP4529540A1 (en) *	2022-05-23	2025-04-02	Cereius, Inc.	Her2-binding agents and uses thereof
KR20250023503A (ko)	2022-06-14	2025-02-18	아블린쓰	T 세포 수용체를 표적화하는 면역글로불린 단일 가변 도메인
MA71603A (fr)	2022-07-27	2025-05-30	Ablynx Nv	Polypeptides se liant à un épitope spécifique du récepteur fc néonatal
AR131494A1 (es)	2022-12-23	2025-03-26	Ablynx Nv	Vehículos de conjugación a base de proteína
CN120529914A (zh)	2023-01-09	2025-08-22	奥德赛治疗股份有限公司	抗tnfr2抗原结合蛋白及其用途
JP2026506075A (ja)	2023-02-17	2026-02-20	アブリンクスエン．ヴェー．	新生児型ｆｃ受容体に結合するポリペプチド
WO2024192065A1 (en)	2023-03-14	2024-09-19	Odyssey Therapeutics, Inc.	Anti-cd25 antigen-binding proteins and uses thereof
CN121511255A (zh)	2023-05-17	2026-02-10	奥德赛治疗股份有限公司	经修饰的单结构域抗体
KR20260028051A (ko)	2023-06-22	2026-03-03	아블린쓰 엔.브이.	사이토카인의 수용체-활성을 조절하기 위한 키메라 단백질
IL325291A (en)	2023-06-29	2026-02-01	Odyssey Therapeutics Inc	Anti-TRAILR2 antigen-binding proteins and their uses
AR133188A1 (es)	2023-07-05	2025-09-03	Ablynx Nv	ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
WO2025051767A1 (en)	2023-09-04	2025-03-13	Sanofi	Polypeptides for use in the treatment of glypican-3-expressing tumours
US20250129145A1 (en)	2023-09-22	2025-04-24	Ablynx N.V.	Bi- and multivalent albumin binders
WO2025080751A2 (en)	2023-10-13	2025-04-17	Odyssey Therapeutics, Inc.	Anti-cdh17 antigen-binding proteins and uses thereof
AR134267A1 (es)	2023-11-08	2025-12-17	Sanofi Sa	Degradador lisosómico basado en cd25 y usos del mismo
TW202540188A (zh)	2023-12-01	2025-10-16	比利時商艾伯霖克斯公司	精準活化的多肽
US20250236673A1 (en)	2023-12-22	2025-07-24	Ablynx N.V.	Protein-based carriers for site-specific amine conjugation
TW202543670A (zh)	2023-12-22	2025-11-16	比利時商艾伯霖克斯公司	用於核內投予之基於蛋白質的接合載劑
WO2025217240A1 (en)	2024-04-10	2025-10-16	Odyssey Therapeutics, Inc.	Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025255558A2 (en)	2024-06-07	2025-12-11	Odyssey Therapeutics, Inc.	Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en)	2024-06-07	2025-12-11	Odyssey Therapeutics, Inc.	Antigen-binding proteins against serum albumin and uses thereof
WO2026006708A2 (en)	2024-06-27	2026-01-02	Odyssey Therapeutics, Inc.	Anti-cd25 antigen-binding proteins and uses thereof
WO2026006809A1 (en)	2024-06-27	2026-01-02	Odyssey Therapeutics, Inc.	Multispecific molecules binding tnfr2 and cd25 and uses thereof
WO2026030375A2 (en)	2024-07-30	2026-02-05	Genzyme Corporation	Lipid nanoparticles and methods of manufacture and use thereof
WO2026052756A1 (en)	2024-09-05	2026-03-12	Ablynx Nv	Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof
WO2026078159A1 (en)	2024-10-10	2026-04-16	Ablynx Nv	Immune cell engagers and methods comprising the same

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
BR9813276A (pt)	1997-10-27	2000-08-22	Unilever Nv	Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma
US6742038B2 (en)	2000-04-07	2004-05-25	Danger, Inc.	System and method of linking user identification to a subscriber identification module
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
US20060002935A1 (en)	2002-06-28	2006-01-05	Domantis Limited	Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) *	2002-06-28	2016-04-26	Domantis Limited	Ligand
ES2263984T3 (es)	2002-06-28	2006-12-16	Domantis Limited	Ligandos doble-especificos con una vida media serica aumentada.
CA2505316C (en)	2002-11-08	2014-08-05	Ablynx N.V.	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1587838B1 (en)	2003-01-10	2015-04-15	Ablynx N.V.	Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
CA2588892A1 (en)	2004-12-02	2006-06-08	Dormantis Limited	Anti-il-1r1 single domain antibodies and therapeutic uses
WO2006122787A1 (en)	2005-05-18	2006-11-23	Ablynx Nv	Serum albumin binding proteins
ES2852423T3 (es)	2005-05-20	2021-09-13	Ablynx Nv	NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
EA200801166A1 (ru)	2005-12-01	2008-12-30	Домантис Лимитед	Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
CA2632866A1 (en)	2005-12-01	2007-06-07	Domantis Limited	Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr)	2005-12-08	2009-12-04	Centre Nat Etd Spatiales	Chaine de reception par satellite
WO2007085814A1 (en)	2006-01-24	2007-08-02	Domantis Limited	Fusion proteins that contain natural junctions
EP2057191A1 (en)	2006-08-18	2009-05-13	Ablynx N.V.	Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CN101646689A (zh) *	2006-09-08	2010-02-10	埃博灵克斯股份有限公司	具有长半衰期的血清清蛋白结合蛋白
CN101796072B (zh)	2007-05-24	2014-09-24	埃博灵克斯股份有限公司	用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
EP2220120A2 (en)	2007-11-27	2010-08-25	Ablynx N.V.	Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
DE102008023620A1 (de)	2008-05-15	2009-11-19	Mettler-Toledo (Albstadt) Gmbh	Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
NZ589036A (en)	2008-05-16	2012-07-27	Ablynx Nv	AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
HRP20170374T1 (hr) *	2008-09-26	2017-05-05	Ucb Biopharma Sprl	Biološki proizvodi
WO2010130832A2 (en)	2009-05-15	2010-11-18	Ablynx N.V.	Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
JP2012532620A (ja)	2009-07-16	2012-12-20	グラクソグループリミテッド	改良型抗血清アルブミン結合単一可変ドメイン
MX2012003939A (es)	2009-09-30	2012-07-30	Glaxo Group Ltd	Fusiones y conjugados de farmaco.
JP2013538566A (ja)	2010-08-13	2013-10-17	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド	改良された抗血清アルブミン結合変異体
JP2013537421A (ja)	2010-08-20	2013-10-03	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド	改良された抗血清アルブミン結合変異体
EP2621953B1 (en) *	2010-09-30	2017-04-05	Ablynx N.V.	Biological materials related to c-met
US11644471B2 (en) *	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
DK2723769T4 (da)	2011-06-23	2022-09-05	Ablynx Nv	Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
CN106046168A (zh) *	2011-06-23	2016-10-26	埃博灵克斯股份有限公司	结合血清白蛋白的蛋白
US20150344568A1 (en) *	2011-06-23	2015-12-03	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012174741A1 (en)	2011-06-24	2012-12-27	Google Inc.	Determining cross-language query suggestion based on query translations
SG2014010482A (en)	2011-08-17	2014-04-28	Glaxo Group Ltd	Modified proteins and peptides
US20130129727A1 (en) *	2011-11-17	2013-05-23	Nanjingjinsirui Science & Technology Biology Corporation	Methods and systems for increasing protein stability
WO2014037419A1 (en) *	2012-09-04	2014-03-13	Vib Vzw	Immunoglobulin single variable domains directed against cd74 and uses derived thereof
US20140186365A1 (en)	2013-01-03	2014-07-03	Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center	Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn
WO2014111550A1 (en)	2013-01-17	2014-07-24	Glaxosmithkline Intellectual Property Development Limited	Modified anti-serum albumin binding proteins
PL3248986T3 (pl)	2014-05-16	2022-05-16	Ablynx Nv	Domeny zmienne immunoglobuliny
JP7001474B2 (ja)	2015-01-21	2022-01-19	インヒブルクス，インコーポレイティド	非免疫原性単一ドメイン抗体
PT3294768T (pt)	2015-05-13	2019-11-05	Ablynx Nv	Polipétidos de recrutamento de células t com base na reatividade do tcr alfa/beta
WO2017070620A2 (en)	2015-10-22	2017-04-27	Modernatx, Inc.	Broad spectrum influenza virus vaccine
WO2017089618A1 (en)	2015-11-27	2017-06-01	Ablynx Nv	Polypeptides inhibiting cd40l
EP3448987A4 (en) *	2016-04-29	2020-05-27	Voyager Therapeutics, Inc.	COMPOSITIONS FOR TREATING A DISEASE
RU2022101604A (ru)	2016-12-07	2022-03-29	Аблинкс Нв	Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
SG10202108972RA (en)	2017-01-17	2021-09-29	Ablynx Nv	Improved serum albumin binders
HRP20241501T1 (hr) *	2017-01-17	2025-01-03	Ablynx Nv	Poboljšana veziva albumina u serumu

2018
- 2018-01-17 HR HRP20241501TT patent/HRP20241501T1/hr unknown
- 2018-01-17 AU AU2018209150A patent/AU2018209150B2/en active Active
- 2018-01-17 DK DK18703213.1T patent/DK3571224T3/da active
- 2018-01-17 IL IL305912A patent/IL305912B2/en unknown
- 2018-01-17 LT LTEPPCT/EP2018/051082T patent/LT3571224T/lt unknown
- 2018-01-17 PL PL18703213.1T patent/PL3571224T3/pl unknown
- 2018-01-17 MX MX2019008536A patent/MX2019008536A/es unknown
- 2018-01-17 SG SG11201906341XA patent/SG11201906341XA/en unknown
- 2018-01-17 CA CA3050574A patent/CA3050574A1/en active Pending
- 2018-01-17 WO PCT/EP2018/051082 patent/WO2018134234A1/en not_active Ceased
- 2018-01-17 SI SI201831172T patent/SI3571224T1/sl unknown
- 2018-01-17 JP JP2019538383A patent/JP7300385B2/ja active Active
- 2018-01-17 HU HUE18703213A patent/HUE068820T2/hu unknown
- 2018-01-17 SG SG10202108973SA patent/SG10202108973SA/en unknown
- 2018-01-17 CN CN202311114345.5A patent/CN117327175A/zh active Pending
- 2018-01-17 US US16/477,927 patent/US11897944B2/en active Active
- 2018-01-17 BR BR112019014600-8A patent/BR112019014600A2/pt unknown
- 2018-01-17 EP EP18703213.1A patent/EP3571224B1/en active Active
- 2018-01-17 IL IL267897A patent/IL267897B2/en unknown
- 2018-01-17 EP EP24191390.4A patent/EP4442708A3/en active Pending
- 2018-01-17 PT PT187032131T patent/PT3571224T/pt unknown
- 2018-01-17 IL IL316293A patent/IL316293A/en unknown
- 2018-01-17 FI FIEP18703213.1T patent/FI3571224T3/fi active
- 2018-01-17 CN CN201880015687.2A patent/CN110461870B/zh active Active
- 2018-01-17 EP EP24191396.1A patent/EP4471058A3/en active Pending
- 2018-01-17 ES ES18703213T patent/ES2994387T3/es active Active
- 2018-01-17 KR KR1020237040677A patent/KR20230165374A/ko not_active Ceased
- 2018-01-17 RS RS20241239A patent/RS66173B1/sr unknown
- 2018-01-17 KR KR1020197024114A patent/KR102653724B1/ko active Active
2019
- 2019-07-17 MX MX2024008521A patent/MX2024008521A/es unknown
- 2019-07-17 MX MX2025010630A patent/MX2025010630A/es unknown
- 2019-07-17 MX MX2024013316A patent/MX2024013316A/es unknown
2022
- 2022-10-20 JP JP2022168448A patent/JP7585272B2/ja active Active
2024
- 2024-01-04 US US18/404,145 patent/US20240294617A1/en active Pending
- 2024-11-06 JP JP2024194438A patent/JP2025024012A/ja active Pending
2025
- 2025-04-07 AU AU2025202453A patent/AU2025202453A1/en active Pending

Also Published As

Publication number	Publication date
ES2994387T3 (en)	2025-01-23
RS66173B1 (sr)	2024-12-31
IL267897B2 (en)	2025-02-01
LT3571224T (lt)	2024-11-11
RU2019125949A3 (da)	2021-03-09
AU2018209150B2 (en)	2025-01-16
US20240294617A1 (en)	2024-09-05
IL305912A (en)	2023-11-01
HRP20241501T1 (hr)	2025-01-03
JP2023002700A (ja)	2023-01-10
EP3571224A1 (en)	2019-11-27
EP3571224B1 (en)	2024-08-07
IL316293A (en)	2024-12-01
AU2025202453A1 (en)	2025-04-24
CA3050574A1 (en)	2018-07-26
IL305912B1 (en)	2024-11-01
JP7300385B2 (ja)	2023-06-29
PT3571224T (pt)	2024-11-08
EP4471058A2 (en)	2024-12-04
EP4442708A2 (en)	2024-10-09
RU2019125949A (ru)	2021-02-19
WO2018134234A1 (en)	2018-07-26
JP2020506898A (ja)	2020-03-05
EP4471058A3 (en)	2025-02-26
HUE068820T2 (hu)	2025-01-28
IL267897A (en)	2019-09-26
KR102653724B1 (ko)	2024-04-02
KR20190104609A (ko)	2019-09-10
US20190367598A1 (en)	2019-12-05
IL305912B2 (en)	2025-03-01
BR112019014600A2 (pt)	2020-02-18
JP2025024012A (ja)	2025-02-19
EP4442708A3 (en)	2024-12-25
SG11201906341XA (en)	2019-08-27
AU2018209150A1 (en)	2019-07-25
MX2024008521A (es)	2024-07-19
CN110461870A (zh)	2019-11-15
IL267897B1 (en)	2024-10-01
SI3571224T1 (sl)	2025-01-31
CN110461870B (zh)	2023-09-29
CN117327175A (zh)	2024-01-02
US11897944B2 (en)	2024-02-13
MX2025010630A (es)	2025-10-01
SG10202108973SA (en)	2021-09-29
MX2019008536A (es)	2019-09-10
KR20230165374A (ko)	2023-12-05
PL3571224T3 (pl)	2025-01-07
FI3571224T3 (fi)	2024-11-05
MX2024013316A (es)	2024-12-06
JP7585272B2 (ja)	2024-11-18

Publication	Publication Date	Title
DK3571225T3 (da)	2024-11-04	Forbedrede serumalbuminbindere
DK3571224T3 (da)	2024-11-11	Forbedrede serumalbuminbindere
IL282960B (en)	2022-03-01	Serum albumin-binding fibronectin type iii domains
IL265321B1 (en)	2023-09-01	Cd3 binding antibodies
IL263840A (en)	2019-01-31	Cd3 binding antibodies
LT3374392T (lt)	2022-01-25	Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai
DK3411065T3 (da)	2021-07-05	Clec9a-bindingsmidler
EP3621994A4 (en)	2020-12-30	MESOTHELIN BINDING PROTEINS
DK3242892T3 (da)	2022-01-24	Modificerede april-bindende antistoffer
DK3529269T3 (da)	2026-02-23	Antistof-konstruktioner
DK3464698T3 (da)	2022-07-25	Bindersystem
EP3661961A4 (en)	2021-04-14	ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN
IL272358B (en)	2022-02-01	Antigen-binding proteins that antagonize leptin receptor
DK3253785T3 (da)	2019-07-08	Hidtil ukendte egfr-bindingsproteiner
EP3579879A4 (en)	2020-12-16	ANTI-BODY ANTI-KIR3DL1
DK3484921T3 (da)	2022-02-07	Anti-IL-22R antistoffer
DK3452515T3 (da)	2025-11-17	Her-2-bindende antistoffer
DE112018000104A5 (de)	2019-05-29	Ablage
LT3456736T (lt)	2021-06-10	Antikūnų variantai
EP3469003A4 (en)	2020-07-29	ANTI-PRL3 ANTIBODIES
DK3448420T3 (da)	2022-12-12	Anti-notch3-antistof
EP3881839C0 (en)	2025-06-04	Bonding agent
UA37626S (uk)	2018-09-10	Напилок
HK1261097A1 (en)	2019-12-27	Improved serum albumin binders